dalfopristin

dalfopristin

 [dal-fo´pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with quinupristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; administered intravenously.

dalfopristin

See Synercid®.
References in periodicals archive ?
CLSI ve EUCAST Kriterlerine Gore Enterokok Suslarinin Kinupristin-Dalfopristine Duyarliliklari EUCAST CLSI Orta Direncli Duyarli Orta Sayi (%) Sayi (%) Sayi (%) Sayi (%) Kinupristin- 3 (3.9) 39 (50.6) 35 (45.5) 8 (10.4) dalfopristin * CLSI Direncli Duyarli Sayi (%) Sayi (%) p ([dagger]) Kinupristin- 33 (42.9) 36 (46.8) <0.001 dalfopristin * CLSI: Clinical Laboratory Standards Institute, EUCAST: European Committee on Antimicrobial Susceptibility Testing.
Quinupristin Dalfopristin: A new antibiotic for severe Gram-positive infections.
pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
"Tn5406, a New Staphylococcal Transposon Conferring Resistance to Streptogramin A and Related Compounds Including Dalfopristin.
AMP--ampicillin, IMP--imipenem, VA--vancomycin, LZD--linezolid, QD--quinupristin/ dalfopristin, SXT--trimethoprim/sulfamethoxazole, TGC--tigecycline.
For patients who have recently suffered from infection with vancomycin resistant Enterococcus (VRE) or MRSA, prophylaxis with linzolid, or quinupristin / dalfopristin can be considered.17 Common Pathogens likely to cause the post-operative infections at surgical site are almost the same as described by Chang and his collogues.18
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin.
Vancomycin, linezolid, gentamicin, moxifloxacin, quinupristin/ dalfopristin, and rifampicin were 100% effective (susceptible).
The failure of glycopeptide antibiotics led to the creation of a new class of drug, the streptogramins, a combination of quinipristin and dalfopristin. Quinupristin/dalfopristin (Synercid[R]) became the drug of choice for MRSA nosocomial infections by the year 2000.
Treatment of methicillin - resistant Staphylococcus aureus infections with quinupristin - dalfopristin in patients intolerant of or failing prior therapy.
aureus Vancomycin 15 mg/kg QID MRSA Quinupristin- 7.5 mg/kg BID Vancomycin- dalfopristin resistant enterococci Linezolid 7.5 mg/kg TID MRSA Fusidic acid 25 mg/kg QID MRSA Ciprofloxacillin 10 mg/kg BID BSBL-producing organisms Imipenem 25 mg/kg QID Anaerobes, ESBL, BSBL, P.
P--Penicillin, ERY--Erythromycin, CX--Cefoxitin, CIP-Ciprofloxacin, COT--Trimethoprim/ Sulfamethoxazole, GM-Gentamicin, VAN--Vancomycin, TEI--Teicoplanin, LZ-Linezolid, RIF--Rifampin, RP--Quinupristin/ Dalfopristin.